Essa Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer
With a commitment to advancing targeted treatments, the company primarily works on potent small molecule inhibitors designed to selectively target and inhibit the activity of specific proteins involved in cancer cell growth and survival. Essa Pharma aims to address significant unmet needs in oncology, particularly in the treatment of prostate cancer, by leveraging its expertise in medicinal chemistry and drug development to bring new options to patients. Through its research and development initiatives, the company strives to enhance patient outcomes and improve the quality of life for those affected by cancer.
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities.
ESSA Pharma shares fell 22.6% at $6.80 yesterday. Explore masofaniten's promising Phase 1/2 results in prostate cancer treatment. Updated data, PSA reductions, and financial strength.
Shares of Humana Inc. (NYSEHUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session.
Gainers LQR House Inc. (NASDAQLQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves.
ESSA Pharma (NASDAQEPIX) reported its Q2 earnings results on Tuesday, May 9, 2023 at 07:00 AM. Here's what investors need to know about the announcement. Earnings ESSA Pharma beat estimated earnings by 20.0%, reporting an EPS of $-0.16 versus an estimate of $-0.2.
One indicator of where a company’s stock might be going in the future can be understood by what insiders may be thinking of the Company’s current stock price and near-term future outlook. Insiders are considered C-Suite Executives, a member of the Board of Directors, and anyone (person or company) that owns over >10.0% of a Company’s outstanding shares.
Gainers 1847 Holdings LLC (NASDAQEFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its existing portfolio.
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQSONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
The Dow Jones closed higher by more than 800 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
